3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
20
pembrolizumab
19
Nivolumab
10
fludarabine
7
Radiosurgery
7
Specimen Handling
6
Ipilimumab
6
Injections
5
Celecoxib
5
poly ICLC
4
Radiation
4
Paclitaxel
4
Melphalan
4
Magnetic Resonance Spectroscopy
4
Gemcitabine
4
Docetaxel
4
Cryosurgery
4
durvalumab
3
cemiplimab
3
Filgrastim
3
Etoposide
3
Cisplatin
3
Blood Specimen Collection
3
Biopsy
3
trastuzumab deruxtecan
2
tislelizumab
2
talimogene laherparepvec
2
spartalizumab
2
fludarabine phosphate
2
bempegaldesleukin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Genetic Counseling
×
Sarcoma
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled